Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT), a commercial messenger RNA medicines company, announced it will release its Q4 and full-year 2024 financial results after market close on March 6, 2025. The company, which focuses on developing infectious disease vaccines and liver and respiratory rare diseases treatments, will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.

Investors can access the earnings call through domestic (1-800-267-6316) or international (1-203-518-9783) dial-in numbers using the Conference ID: ARCTURUS. A webcast link will also be available.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 6, 2025.

Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call

• Thursday, March 6, 2025 @4:30 p.m. ET
• Domestic: 1-800-267-6316
• International: 1-203-518-9783
• Conference ID: ARCTURUS
• Webcast: Link

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250224606860/en/

Arcturus Therapeutics

Public Relations & Investor Relations

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@ArcturusRx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When will Arcturus Therapeutics (ARCT) release its Q4 2024 earnings?

Arcturus Therapeutics will release its Q4 and full-year 2024 financial results after market close on Thursday, March 6, 2025.

What time is Arcturus Therapeutics (ARCT) Q4 2024 earnings call?

The earnings conference call and webcast will be held at 4:30 p.m. Eastern Time on March 6, 2025.

How can investors join Arcturus Therapeutics (ARCT) Q4 2024 earnings call?

Investors can join via domestic number 1-800-267-6316, international number 1-203-518-9783, using Conference ID: ARCTURUS, or through the webcast link.

What is Arcturus Therapeutics' (ARCT) main business focus?

Arcturus Therapeutics is a commercial messenger RNA medicines company focused on developing infectious disease vaccines and treatments for liver and respiratory rare diseases.